kits.traumatologi.no

Antibody-dependent cellular cytotoxicity (ADCC) is an important immune mechanism for antibodies. For the past years, ADCC-enhanced therapeutic antibodies have been shown to exhibit unprecedented anti-cancer effects in vivo. During the research, characterizing ADCC activity and determining its impact on clinical efficacy is critical. With the leverage of our knowledge and rich experience in antibody engineering and glycosylation control, we are committed to developing next-generation ADCC antibodies for our customers.